Photoacoustic diagnosis of pharmacokinetics and vascular shutdown effects in photodynamic treatment with indocyanine green-lactosome for a subcutaneous tumor in mice

Tsunoi, Yasuyuki; Araki, Koji; Ozeki, Eiichi; Hara, Isao; Shiotani, Akiko; Terakawa, Mitsuhiro; Sato, Shunichi

doi:10.1016/j.pdpdt.2019.04.031

Cited by 8 publications

(10 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tsujimoto et al demonstrated that ICG-loaded lactosomes (ICGm) prepared from ICG-PLLA and AB-type polysarcosine-PLLA, with particle sizes of 40–50 nm, selectively accumulated in tumor tissues [ 9 ]. The photoacoustic signal originating from ICGm was increased at 18 h after injection in a mouse model with subcutaneous tumors, indicating efficient accumulation of ICGm in the tumor [ 13 ].…”

Section: Molecular Design Of Indocyanine Green-loaded Lactosomesmentioning

confidence: 99%

“…Although fluorescence imaging has been used to assess the pharmacokinetics of ICG-lactosomes in vivo, this method provides no depth-resolved information. As shown in Figure 3 , Tsunoi et al applied photoacoustic imaging to visualize the depth distribution of ICG-lactosomes in a mouse model of subcutaneous tumor [ 13 ]. ICG was illuminated during photoacoustic imaging using a short laser pulse with a wavelength of 796 nm.…”

Section: Molecular Design Of Indocyanine Green-loaded Lactosomesmentioning

confidence: 99%

“…However, ICG in the blood tends to bind to albumin, which confines most of the bolus to the intravascular space until albumin-mediated hepatic uptake and subsequent excretion into bile [ 11 , 12 ]. Alternatively, ICG-loaded lactosomes remain stable during long-term blood circulation and can accumulate in tumor tissues, where they can act as photosensitizers that generate reactive oxygen species upon application of light of the appropriate wavelength for ICG excitation, about 780 nm [ 13 ]. Furthermore, it is possible to label the surface of lactosomes with antibodies to selectively deliver drugs and genes to cancer cells.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Theranostics Using Indocyanine Green Lactosomes

Kaibori

Matsui

Hayashi

2022

Cancers

View full text Add to dashboard Cite

Lactosomes™ are biocompatible nanoparticles that can be used for cancer tissue imaging and drug delivery. Lactosomes are polymeric micelles formed by the self-assembly of biodegradable amphiphilic block copolymers composed of hydrophilic polysarcosine and hydrophobic poly-L-lactic acid chains. The particle size can be controlled in the range of 20 to 100 nm. Lactosomes can also be loaded with hydrophobic imaging probes and photosensitizers, such as indocyanine green. Indocyanine green-loaded lactosomes are stable for long-term circulation in the blood, allowing for accumulation in cancer tissues. Such lactosomes function as a photosensitizer, which simultaneously enables fluorescence diagnosis and photodynamic therapy. This review provides an overview of lactosomes with respect to molecular design, accumulation in cancer tissue, and theranostics applications. The use of lactosomes can facilitate the treatment of cancers in unresectable tissues, such as glioblastoma and head and neck cancers, which can lead to improved quality of life for patients with recurrent and unresectable cancers. We conclude by describing some outstanding questions and future directions for cancer theranostics with respect to clinical applications.

show abstract

Section: Molecular Design Of Indocyanine Green-loaded Lactosomesmentioning

confidence: 99%

Section: Molecular Design Of Indocyanine Green-loaded Lactosomesmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Theranostics Using Indocyanine Green Lactosomes

Kaibori

Matsui

Hayashi

2022

Cancers

View full text Add to dashboard Cite

show abstract

“…Hence, the design of simpler Lactosome through intelligible approaches is essential for future clinical evaluation and application. Up to now, pharmaceutical companies were investigating the possibilities of commercializing photodynamic therapy and photoacoustic diagnosing using the ICG-Lactosome [180,181], while the AB-type Lactosome is currently under consideration by licensing it to an overseas pharmaceutical manufacturer at a non-clinical level.…”

Section: Future Perspective and Limitationsmentioning

confidence: 99%

A Novel 89Zr-labeled DDS Device Utilizing Human IgG Variant (scFv): “Lactosome” Nanoparticle-Based Theranostics for PET Imaging and Targeted Therapy

Lim

Ohtsuki

Takenaka

et al. 2021

Life

Self Cite

View full text Add to dashboard Cite

“Theranostics,” a new concept of medical advances featuring a fusion of therapeutic and diagnostic systems, provides promising prospects in personalized medicine, especially cancer. The theranostics system comprises a novel 89Zr-labeled drug delivery system (DDS), derived from the novel biodegradable polymeric micelle, “Lactosome” nanoparticles conjugated with specific shortened IgG variant, and aims to successfully deliver therapeutically effective molecules, such as the apoptosis-inducing small interfering RNA (siRNA) intracellularly while offering simultaneous tumor visualization via PET imaging. A 27 kDa-human single chain variable fragment (scFv) of IgG to establish clinically applicable PET imaging and theranostics in cancer medicine was fabricated to target mesothelin (MSLN), a 40 kDa-differentiation-related cell surface glycoprotein antigen, which is frequently and highly expressed by malignant tumors. This system coupled with the cell penetrating peptide (CPP)-modified and photosensitizer (e.g., 5, 10, 15, 20-tetrakis (4-aminophenyl) porphyrin (TPP))-loaded Lactosome particles for photochemical internalized (PCI) driven intracellular siRNA delivery and the combination of 5-aminolevulinic acid (ALA) photodynamic therapy (PDT) offers a promising nano-theranostic-based cancer therapy via its targeted apoptosis-inducing feature. This review focuses on the combined advances in nanotechnology and material sciences utilizing the “89Zr-labeled CPP and TPP-loaded Lactosome particles” and future directions based on important milestones and recent developments in this platform.

show abstract

“…OA has been recently used for monitoring changes in vascular structure and blood oxygenation following PDT [ 23 ]. Tumor response to HPPH-based PDT included a time-dependent decrease in vessel diameter and vascular area [ 36 ]; such vascular shutdown was also revealed by OA after PDT with ICG-lactosome [ 37 ]. Rapid vessel occlusion and hemorrhage formation were demonstrated in response to treatment with Padeliporfin [ 38 ].…”

Section: Introductionmentioning

confidence: 99%

Combined Fluorescence and Optoacoustic Imaging for Monitoring Treatments against CT26 Tumors with Photoactivatable Liposomes

Turchin

Bano

Kirillin

et al. 2021

Cancers

View full text Add to dashboard Cite

The newly developed multimodal imaging system combining raster-scan optoacoustic (OA) microscopy and fluorescence (FL) wide-field imaging was used for characterizing the tumor vascular structure with 38/50 μm axial/transverse resolution and assessment of photosensitizer fluorescence kinetics during treatment with novel theranostic agents. A multifunctional photoactivatable multi-inhibitor liposomal (PMILs) nano platform was engineered here, containing a clinically approved photosensitizer, Benzoporphyrin derivative (BPD) in the bilayer, and topoisomerase I inhibitor, Irinotecan (IRI) in its inner core, for a synergetic therapeutic impact. The optimized PMIL was anionic, with the hydrodynamic diameter of 131.6 ± 2.1 nm and polydispersity index (PDI) of 0.05 ± 0.01, and the zeta potential between −14.9 ± 1.04 to −16.9 ± 0.92 mV. In the in vivo studies on BALB/c mice with CT26 tumors were performed to evaluate PMILs’ therapeutic efficacy. PMILs demonstrated the best inhibitory effect of 97% on tumor growth compared to the treatment with BPD-PC containing liposomes (PALs), 81%, or IRI containing liposomes (L-[IRI]) alone, 50%. This confirms the release of IRI within the tumor cells upon PMILs triggering by NIR light, which is additionally illustrated by FL monitoring demonstrating enhancement of drug accumulation in tumor initiated by PDT in 24 h after the treatment. OA monitoring revealed the largest alterations of the tumor vascular structure in the PMILs treated mice as compared to BPD-PC or IRI treated mice. The results were further corroborated with histological data that also showed a 5-fold higher percentage of hemorrhages in PMIL treated mice compared to the control groups. Overall, these results suggest that multifunctional PMILs simultaneously delivering PDT and chemotherapy agents along with OA and FL multi-modal imaging offers an efficient and personalized image-guided platform to improve cancer treatment outcomes.

show abstract

Photoacoustic diagnosis of pharmacokinetics and vascular shutdown effects in photodynamic treatment with indocyanine green-lactosome for a subcutaneous tumor in mice

Cited by 8 publications

References 31 publications

Theranostics Using Indocyanine Green Lactosomes

Theranostics Using Indocyanine Green Lactosomes

A Novel 89Zr-labeled DDS Device Utilizing Human IgG Variant (scFv): “Lactosome” Nanoparticle-Based Theranostics for PET Imaging and Targeted Therapy

Combined Fluorescence and Optoacoustic Imaging for Monitoring Treatments against CT26 Tumors with Photoactivatable Liposomes

Contact Info

Product

Resources

About